Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-22

Clinical Trial Update: Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating TAK-583 for diabetic peripheral neuropathy has completed, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAK-583

Snippet

Sponsor: Takeda | Conditions: Diabetic Neuropathies | Phase 2 | Status: COMPLETED